Evaluation of SMOFlipid in Pediatric Intestinal-Failure Patients and Its Effects on Essential Fatty Acid Levels.

Beatrice E HoStacie C ChanAnna V FainoMelissa MortensenNila WilliamsonPatrick J JavidSimon P HorslenDanielle Wendel

Published in: JPEN. Journal of parenteral and enteral nutrition (2020)

In 20 pediatric IF patients, SMOFlipid allowed greater ω-6 FA provision while maintaining ω-3 FA, hepatic function, and patient growth. This longitudinal study identified improved FA profile associated with SMOFlipid use in comparison with SO with or without FO.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
fatty acid
peritoneal dialysis
patient reported outcomes